Lexeo Therapeutics (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 25,947 Shares

Posted by Stanley Muller on Jul 2nd, 2026

Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Get Free Report) CEO Richard Nolan Townsend sold 25,947 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total transaction of $116,242.56. Following the transaction, the chief executive officer directly owned 377,817 shares in the company, valued at approximately $1,692,620.16. The trade was a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Richard Nolan Townsend also recently made the following trade(s):

On Monday, May 18th, Richard Nolan Townsend sold 3,342 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $5.06, for a total transaction of $16,910.52.
On Monday, April 6th, Richard Nolan Townsend sold 55,000 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $5.69, for a total transaction of $312,950.00.

Lexeo Therapeutics Trading Down 4.5%

Shares of Lexeo Therapeutics stock opened at $4.45 on Thursday. Lexeo Therapeutics, Inc. has a twelve month low of $3.60 and a twelve month high of $10.99. The firm has a market capitalization of $349.41 million, a PE ratio of -3.07 and a beta of 1.42. The firm’s 50-day moving average price is $5.12 and its 200 day moving average price is $6.63.

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.04. On average, sell-side analysts predict that Lexeo Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Chardan Capital reissued a “buy” rating and issued a $17.00 price objective on shares of Lexeo Therapeutics in a research note on Monday, May 11th. Weiss Ratings cut shares of Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 25th. JPMorgan Chase & Co. dropped their target price on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, June 25th. Finally, Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $18.75.

View Our Latest Analysis on LXEO

Institutional Investors Weigh In On Lexeo Therapeutics

Large investors have recently made changes to their positions in the stock. Bank of America Corp DE lifted its position in Lexeo Therapeutics by 206.7% during the first quarter. Bank of America Corp DE now owns 491,532 shares of the company’s stock worth $2,821,000 after buying an additional 331,244 shares in the last quarter. ADAR1 Capital Management LLC grew its holdings in Lexeo Therapeutics by 5.3% in the 1st quarter. ADAR1 Capital Management LLC now owns 1,467,350 shares of the company’s stock valued at $8,423,000 after buying an additional 74,189 shares in the last quarter. Orbimed Advisors LLC increased its stake in shares of Lexeo Therapeutics by 69.5% in the 1st quarter. Orbimed Advisors LLC now owns 3,602,450 shares of the company’s stock worth $20,678,000 after acquiring an additional 1,477,450 shares during the last quarter. Affinity Asset Advisors LLC increased its stake in shares of Lexeo Therapeutics by 57.8% in the 1st quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company’s stock worth $28,988,000 after acquiring an additional 1,850,211 shares during the last quarter. Finally, Spruce Street Capital LP raised its holdings in shares of Lexeo Therapeutics by 430.6% during the 1st quarter. Spruce Street Capital LP now owns 928,593 shares of the company’s stock worth $5,330,000 after acquiring an additional 753,593 shares during the period. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

About Lexeo Therapeutics

(Get Free Report)

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.